[CAS NO. 106577-39-3] Hederacolchiside A1

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [106577-39-3]

Catalog

HY-N6950

Brand

MCE

CAS

106577-39-3

DESCRIPTION [106577-39-3]

Overview

MDL	-
Molecular Weight	897.10
Molecular Formula	C47H76O16
SMILES	C[C@]12[C@]3(C([C@@]4([H])[C@](C(O)=O)(CCC(C)(C)C4)CC3)=CC[C@]1([H])[C@@]5([C@@](C(C)([C@@H](O[C@@]6([H])[C@@H]([C@H]([C@@H](O[C@]7([H])O[C@@H]([C@@H](O)[C@H](O)[C@H]7O)CO)CO6)O)O[C@@]8([H])[C@@H]([C@@H]([C@@H](O)[C@H](C)O8)O)O)CC5)C)([H])CC2)C)C

For research use only. We do not sell to patients.

Summary

Hederacolchiside A1, isolated from Pulsatilla chinensis , suppresses proliferation of tumor cells by inducing apoptosis through modulating PI3K/Akt/mTOR signaling pathway ^[1] . Hederacolchiside A1 has antischistosomal activity, affecting parasite viability both in vivo and in vitro ^[2] .

IC50 & Target

PI3K

mTOR

In Vitro

Hederacolchiside A1 reduces the mitochondrial membrane potential and Bcl-2 protein levels, whereas cleaved caspase-3 was higher ^[1] .
Hederacolchiside A1 effectively inhibits the phosphorylations of phosphatidylinositol 3 kinase (PI3K), protein kinase B (Akt), and mammalian target of rapamycin (mTOR) ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

hederacolchiside A1 (3.0, 4.5, and 6.0 mg/kg, ip) can significantly inhibit the weight of tumor in an H22 xenograft model ^[1] .
Hederacolchiside A1 (3.25, 7.5, and 15.0 mg/kg, ig) can significantly inhibit the weight of tumor in nude mice xenograft tumor models using human breast carcinoma MCF-7 cells ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Appearance

Solid

Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 111.47 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.1147 mL	5.5735 mL	11.1470 mL
5 mM	0.2229 mL	1.1147 mL	2.2294 mL
10 mM	0.1115 mL	0.5574 mL	1.1147 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (2.79 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (2.79 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (2.79 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

Olean-12-en-28-oic acid, 3-[(O-6-deoxy-α-L-mannopyranosyl-(1→2)-O-[β-D-glucopyranosyl-(1→4)]-α-L-arabinopyranosyl)oxy]-, (3β)-

(3β)-3-[(O-6-Deoxy-α-L-mannopyranosyl-(1→2)-O-[β-D-glucopyranosyl-(1→4)]-α-L-arabinopyranosyl)oxy]olean-12-en-28-oic acid

Hederacolchiside A₁

Oleanolic acid-3-O-α-L-rhamnopyranosyl-(1->2)-[β-D-glucopyranosyl-(1->4)]-α-L-arabinopyranoside

Raddeanoside R₁₃

Oleanolic acid 3-O-α-L-rhamnopyranosyl-(1→2)-[β-D-glucopyranosyl-(1→4)]-α-L-arabinopyranoside